Dynamic Technology Lab Private Ltd Takes Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Dynamic Technology Lab Private Ltd acquired a new position in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 45,950 shares of the company’s stock, valued at approximately $320,000.

Several other institutional investors also recently bought and sold shares of BCYC. Cerity Partners LLC bought a new position in Bicycle Therapeutics during the 1st quarter worth approximately $113,000. Jefferies Financial Group Inc. purchased a new stake in shares of Bicycle Therapeutics during the first quarter valued at approximately $3,471,000. Westfield Capital Management Co. LP grew its holdings in shares of Bicycle Therapeutics by 1.8% in the first quarter. Westfield Capital Management Co. LP now owns 2,657,305 shares of the company’s stock worth $22,561,000 after purchasing an additional 46,968 shares during the last quarter. Tocqueville Asset Management L.P. increased its stake in shares of Bicycle Therapeutics by 24.5% in the first quarter. Tocqueville Asset Management L.P. now owns 18,300 shares of the company’s stock worth $155,000 after buying an additional 3,600 shares during the period. Finally, Candriam S.C.A. increased its stake in shares of Bicycle Therapeutics by 10.8% in the first quarter. Candriam S.C.A. now owns 1,205,207 shares of the company’s stock worth $10,232,000 after buying an additional 117,331 shares during the period. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Morgan Stanley cut their price target on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 12th. Oppenheimer reissued an “outperform” rating and issued a $44.00 target price (down from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. JMP Securities set a $12.00 price target on Bicycle Therapeutics in a research report on Friday, October 31st. Citizens Jmp lifted their price objective on Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Friday, October 31st. Finally, Truist Financial initiated coverage on Bicycle Therapeutics in a research note on Monday. They set a “hold” rating and a $10.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bicycle Therapeutics has an average rating of “Hold” and a consensus target price of $19.73.

Insider Activity

In other news, CEO Kevin Lee sold 3,231 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $8.41, for a total value of $27,172.71. Following the sale, the chief executive officer directly owned 475,310 shares of the company’s stock, valued at $3,997,357.10. The trade was a 0.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 8,527 shares of company stock worth $71,738 in the last ninety days. 8.50% of the stock is currently owned by company insiders.

Bicycle Therapeutics Trading Up 1.9%

Shares of BCYC stock opened at $6.87 on Wednesday. The company’s fifty day moving average price is $7.48 and its 200-day moving average price is $7.67. The stock has a market cap of $476.57 million, a PE ratio of -1.90 and a beta of 1.48. Bicycle Therapeutics PLC Sponsored ADR has a 12 month low of $6.03 and a 12 month high of $21.50.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.24. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. The company had revenue of $11.73 million during the quarter, compared to analysts’ expectations of $8.25 million. On average, sell-side analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.